

**CIRM OUTSIDE REVIEW PANEL**  
**OCTOBER 13, 14 & 15, 2010**  
**SAN FRANCISCO, CA**  
**(PUBLIC BIOS)**

**DR. ALAN BERNSTEIN** is the inaugural executive director of the Global HIV Vaccine Enterprise, an international alliance of researchers, funders and advocates committed to accelerating the development of an HIV vaccine. The Global HIV Vaccine Enterprise is charged by its founders with setting scientific priorities, mobilizing resources, and improving collaboration in the HIV vaccine field. Originally proposed by 24 leading HIV vaccine researchers in 2003, the Enterprise has to date mobilized more than US\$750 million in support of its scientific plan.

Dr. Bernstein was previously the founding president of the Canadian Institutes of Health Research (CIHR). During his seven years there, he built CIHR into one of the world's leading research agencies, supporting more than 11,000 health researchers with an annual budget of US\$1 billion.

Dr. Bernstein received his Ph.D. in Medical Biophysics at the University of Toronto. Following postdoctoral work in London where he first began working on retroviruses, he returned to Canada to join the faculty of the Ontario Cancer Institute. He later served as head of the Division of Molecular and Developmental Biology at the Samuel Lunenfeld Research Institute at Mount Sinai Hospital, and then its director of research.

Author of over 200 peer-reviewed scientific publications, Dr. Bernstein is an internationally renowned researcher who has made extensive contributions to the study of embryonic development, stem cells, hematopoiesis and cancer. Dr. Bernstein has received numerous awards for his research and contributions to science, including the McLaughlin Medal of the Royal Society of Canada, the Robert L. Noble Prize from the National Cancer Institute of Canada, the Genetics Society of Canada Award of Excellence, the 2001 Australian Society of Medical Research Medal, an honorary degree from Dalhousie University, the 2007 Medaille du merite from the Institut de Recherche Clinique de Montreal, and the Order of Canada in 2002. Dr. Bernstein chairs and sits on a number of review boards and advisory committees in Canada, the US, the UK, Singapore, and Australia.

---

**DR. GEORGE DALEY** is director of Stem Cell Transplantation at the Children's Hospital and Dana Farber Cancer Institute, The Samuel E. Lux IV Chair in Hematology, and associate professor of Biological Chemistry and Molecular Pharmacology at Harvard Medical School. Dr. Daley's lab was among the first to produce human induced pluripotent stem cells and disease-specific stem cells. As a clinician-scientist, Dr. Daley has extensive experience in translating promising science into novel therapeutics. Dr. Daley is the chair of the Scientific Advisory Board of iPerian.

---

**PROFESSOR SIR MARTIN EVANS** - Nobel Laureate, Director of the School of Biosciences and Professor of Mammalian Genetics of Cardiff University.

Winner of the Nobel Prize for Medicine, Professor Sir Martin Evans gained his BA in Biochemistry from Christ College, University of Cambridge in 1963. He received an MA in 1966 and a DSc in 1996. In 1969 he was awarded a PhD degree from University College, London.

After graduating from Cambridge, he decided on a career studying the genetic control of vertebrate development. His early PhD research led him to explore the use of cultures of mouse teratocarcinoma stem cells in tissue culture systems. He was the first to maintain these cells in tissue culture under conditions where their ability to differentiate was retained indefinitely.

It was not until 1981, after his return to Cambridge, that he was able to isolate similar cells from normal mouse embryos. Subsequently he and his colleagues demonstrated that these cells which became known as "Embryonic Stem Cells" (ES cells) were able to be used to fully regenerate fertile breeding mice from the tissue culture cells and that these could therefore carry mutations introduced and selected or screened for in culture. This is now the basis of all mouse knockout and targeted genetic manipulation.

These fundamental developments created new routes to experimental mammalian genetics and hence functional genomics. Since then, Sir Martin, who came to Cardiff University's School of Biosciences in 1999, has been exploiting gene knockout and gene trap methods both for novel discovery and to create animal models of human disease. From his laboratory came the first demonstration of gene therapy to cure the deficit in Cystic Fibrosis in a whole animal and recently, from a mutated mouse model, insights into the breast cancer gene BRCA2 function.

Sir Martin has published more than 120 scientific papers. He was elected a Fellow of the Royal Society in 1993 and is a founder Fellow of the Academy of Medical Sciences. In 1993 he was awarded the Walter Cottman Fellowship and the William Bate Hardy Prizes. He was awarded the prestigious Albert Lasker Award for Basic Medical Research in the US in 2001. In 2002 he was awarded an honorary doctorate from Mount Sinai School of Medicine in New York, regarded as one of the world's foremost centres for medical and scientific training.

---

**DR. JUDY ILLES**, Canada Research Chair in Neuroethics, is Director of the National Core for Neuroethics at the University of British Columbia, Professor of Neurology, and Adjunct Professor with the School of Population and Public Health. She is faculty of the Brain Research Centre, of the Vancouver Coastal Health Research Institute, and a founding fellow of the Institute of Mental Health at UBC. She is a co-founder of the Neuroethics Society, a member of the Internal Advisory Board for the Institute of Neurosciences, Mental Health and Addiction (INMHA) of the Canadian Institutes of Health Research (CIHR), a member of the Institute of Medicine, Forum on Neuroscience and Neurological Disorders, and a member of the Dana Alliance for Brain Initiatives. Dr. Illes is editor of the American Journal of Bioethics (AJOB) - Neuroscience, and chair of Women in World Neuroscience for the International Brain Research Organization.

---

**-RICHARD A. INSEL, M.D.** -- Executive Vice President of Research for the Juvenile Diabetes Research Foundation, where he has responsibility for heading up the strategic direction and oversight of all JDRF research projects.

Dr. Insel has had a distinguished medical and research career in pediatric immunology. Prior to joining JDRF in 2003, he held various leadership positions at the University of Rochester Medical Center during a 26-year tenure there. Dr. Insel was the founding director of the Center for Human Genetics and Molecular Pediatric Disease and a member of the departments of pediatrics and microbiology & immunology. Among other responsibilities, Dr. Insel served as Acting Chair of Pediatrics; Professor of Pediatrics, Microbiology & Immunology, and the Cancer Center; Associate Chair for Pediatric Research; Director of the Strong Children's Research Center; and Chief of the Division of Pediatric Immunology, Allergy and Rheumatology.

Dr. Insel was the scientific co-founder of Praxis Biologics, a biotechnology company established in 1983 and subsequently acquired by Wyeth, the global pharmaceutical and health care products company. Praxis Biologics was responsible for bringing a new vaccine to market that resulted in the virtual elimination of the most common form of childhood meningitis among American infants and children.

Dr. Insel has served on the National Advisory Allergy and Infectious Diseases Council of the National Institutes of Health. He has been a Visiting Associate Professor of Biochemistry and Biophysics at Columbia University's College of Physicians and Surgeons, a fellow in pediatrics (research) at Harvard Medical School, and a fellow in medicine (immunology) at Children's Hospital Medical Center in Boston. He also served in the Laboratory of Parasitic Immunochimistry at the Centers for Disease Control in Atlanta.

---

**DR. RICHARD KLAUSNER** was formerly the global health executive director of the Bill and Melinda Gates Foundation's Global Health program, whose overarching goal is to improve global health equity. Dr. Klausner previously served as director of the National Cancer Institute (NCI), where he led one of the world's largest research and health agencies, creating successful national and international programs aimed at applying science and technology to improving the public health. In addition, Dr Klausner is currently engaged as an independent consultant for biotech and global health and is a managing director of The Column Group, a strategy-based venture fund. Dr. Klausner is well known for his work in cell and molecular biology. Dr. Klausner has served as chief of the cell biology and metabolism branch of the National Institute of Child Health and Human Development. He has served on numerous advisory committees and is the past president of the American Society for Clinical Investigation. He is the author of more than 300 scientific articles and several books, and has received numerous awards and honors. Dr. Klausner has served as a senior fellow at the National Academies of Science, advisor to the presidents of the Academies for counter-terrorism, and liaison to the White House Office of Science and Technology Policy. In addition, Dr. Klausner lead the efforts of the National Academies of Science to write standards for science education for the United States. He is a member of the National Academy of Sciences and the Institute of Medicine and the America Academy of Arts and Sciences

---

**-MYRTLE POTTER** is recognized as one of America's foremost health care leaders, founded **Myrtle Potter & Company, LLC** in 2005 and currently serves as CEO and President. As a trusted voice in healthcare, Myrtle has dedicated three decades of service and leadership to America's most successful global life science companies. She has leveraged her vast experience operating large pharmaceutical and biotechnology businesses to better serve the needs of health care companies, consumers and patients worldwide.

Myrtle was President and Chief Operating Officer of **Genentech, Inc.**, from 2000 to 2005, where she helped steer the company through one of the most successful periods in its history. Genentech achieved record sales and earnings growth during each of the five years she led the company, and under her leadership the company launched seven breakthrough molecules including Avastin, the world's first antiangiogenesis product for the treatment of cancer.

Prior, Myrtle was president of **Bristol-Myers Squibb's** \$4 billion, 3,500-person U.S. Cardiovascular/Metabolics business. Under her leadership this business was the largest, fastest growing and most profitable of all of the BMS divisions.

Before working for Bristol-Myers Squibb, Myrtle worked at **Merck & Co., Inc.** for fourteen years. During her tenure at Merck, she established the new pharmaceutical company, Astra/Merck, Inc. that later merged with Zeneca to form the company now known as AstraZeneca. Following that initiative, she directed the marketing of the blockbuster prescription drug Prilosec and set it on course to become the largest selling pharmaceutical product in the world at that time. Her last position at Merck was as vice president of an \$800 million U.S. pharmaceutical business unit.

Myrtle holds numerous leadership positions in both for-profit and non-profit organizations. She currently serves on the board of directors of **Medco Health Solutions, Inc.**, a Fortune 51 pharmaceutical benefit management company and on the Dean's Advisory Board of the **Stanford Business School**. She served on the board of directors of **Amazon.com**, from 2004 to 2009. In 2003 she was appointed by the Governor of California to serve on the five-member Citizen's Financial Accountability Oversight Committee of the **California Institute for Regenerative Medicine**, where she served until 2009.

**-NANCY WEXLER, PH.D.** is the Higgins Professor of Neuropsychology in the Departments of Neurology and Psychiatry of the College of Physicians and Surgeons at Columbia University, as well as the President of the Hereditary Disease Foundation. Involved in public policy, individual counseling, genetic research, and federal health administration, she is most widely known for her important scientific contribution on Huntington's disease. A 20-year study of the world's largest family with Huntington's disease, in Venezuela, developing a pedigree of over 18,000 individuals and collecting over 4,000 blood samples helped lead to the identification of the Huntington's disease gene at the tip of human chromosome 4. These same blood samples have assisted in the mapping of other disease genes, including those responsible for familial Alzheimer's disease, kidney cancer, two kinds of neurofibromatosis, Amyotrophic Lateral Sclerosis(ALS), dwarfism and others. One result of this work was the development of a presymptomatic test which could tell who is carrying the fatal gene prior to the onset of symptoms.

Wexler received an A.B. from Radcliffe in 1967 and a Ph.D. in clinical psychology from the University of Michigan in 1974. She currently holds or has held numerous public policy positions, including Chair of the Joint NIH/DOE Ethical, Legal and Social Issues Working Group of the National Center for Human Genome Research, Chair of the Human Genome Organization (HUGO) and Member of the Institute of Medicine. Wexler has served as a member of the board of directors of the American Association for the Advancement of Science and on the Advisory Committee on Research on Women's Health, NIH. She has received numerous honors and awards, including several honorary doctorates. Dr. Wexler was recently elected to be a Fellow at the Royal College of Physicians; a Member of the American Academy of Arts and Sciences; a Fellow at the American Association for the Advancement of Science, Section on Neuroscience; a Member of the European Academy of Sciences and Arts; and to the position of Councilor, Society for Neuroscience. She is an honorary Fellow of the New York Academy of Sciences and a Member of the Institute of Medicine, National Academy of Sciences. In 1993, she received the Albert Lasker Public Service Award.

---

## POSSIBLE ADDITION – WAITING FOR RESPONSE

**-REAR ADMIRAL SUSAN J. BLUMENTHAL, M.D., M.P.A.** provided distinguished service for over twenty years as a leading national U.S. government health expert and spokesperson. She served as Assistant Surgeon General of the United States, as the first ever Deputy Assistant Secretary for Women's Health, and as Senior Global and E-Health Advisor, in the U.S. Department of Health and Human Services. She also was a White House advisor on health issues. Dr Blumenthal has served as the top medical advisor to the Secretary of the US Department of Agriculture, and as a Branch Chief at the National Institutes of Health. She is currently Distinguished Advisor on Health and Medicine at the Center for the Study of the Presidency, a Clinical Professor at Georgetown and Tufts Schools of Medicine, and President of a new Global Health initiative. Dr. Blumenthal has served as Distinguished Visiting Professor of Women's Studies at Brandeis University, as a Visiting Professor at the Mayo Clinic and Stanford University in Washington and as a Fellow at Harvard University's School of Government. A champion for improving health, she has done pioneering work in advancing women's health. An international leader in advancing global health, she has been a major force in the response to terrorism, emergency preparedness, emerging disease threats including avian flu, obesity, mental illness, cancer, AIDS, suicide and violence prevention. Admiral Blumenthal has been at the forefront of national efforts to emphasize equity in the health care system, the power of prevention and in internet medicine establishing several of the government's leading, award winning health websites. She has chaired numerous national and international health commissions, committees and conferences. Dr. Blumenthal served as the host and medical director of an award winning television series on health and as the health columnist for *US News and World Report* and *Elle* magazines. She is a medical advisor to a PBS health initiative and to a Discovery Channel/American Film Institute global health film series. Dr. Blumenthal is on the Board of Directors of several philanthropic and educational institutions including Save the Children, the Academy of Achievement, Stanford in Washington and the Meridian International Center. Named by the *Medical Herald* and the National Library of Medicine as one of the most influential and important women in medicine and by the *New York Times* as one of the top doctors in the women's health field, Admiral Blumenthal is the recipient of numerous awards, medals and honorary doctorates for her landmark contributions to improving health.